The sell-offs of these stocks were driven by issues that were never going to last.Finding attractive dividend stocks you can hold isn't too difficult. Finding dividend stocks you can comfortably buy and hold forever is a different story. For your truly long-term holdings, you'll want companies that are not only leading names with staying power, but that also operate in resilient markets -- a rarer set of criteria.Of course, if such a stock is on sale at the time you're ready to take the plunge, so much the ...

POLAND - 2024/11/22: In this photo illustration, the Bristol-Myers Squibb company logo is seen ... [+] displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesGiven its better prospects, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pharmaceutical pick over Johnson & Johnson stock (NYSE: JNJ). BMY stock trades at 8.3x its forward expected earnings (2025), versus 14.7x for JNJ. However, ...

When I last wrote about the pharmaceuticals company Bristol-Myers Squibb Company (NYSE: BMY ) in August, I had given it a Sell rating for the short term. This was based on the likelihood of a price drop on the releaseManika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green economy. Her investing group, Green Growth Gia ...

Generating thousands of dollars of recurring income can be a great way to make you less reliant on employment income or retirement benefits. If you have savings that you can afford to invest in stocks, there are multiple high-yielding dividend investments to consider right now. While many investors have been focusing on growth stocks and hype surrounding artificial intelligence, dividend stocks have been on the back burner of late, which could make now an advantageous time to invest in them.Three dividend s ...

Summary of Bristol-Myers Squibb Company Conference Call Company Overview - **Company**: Bristol-Myers Squibb Company (NYSE: BMY) - **Event**: Jefferies London Healthcare Conference - **Date**: November 19, 2024 - **Participants**: David Elkins (CFO), Unidentified Company Representative Key Points Industry and Company Performance - The focus for the year is on execution, with two strong quarters indicating a transformation within the company [2][11] - The growth portfolio has seen a **20% increase** in constant currency, now representing nearly **50%** of the company's revenue [3][12] - Legacy portfolio remains a significant cash generator for the business [2] Product Pipeline and Upcoming Approvals - **Cobenfy**: Recently acquired product with promising feedback from physicians; expected to be a multibillion-dollar product with multiple indications [3][6] - Upcoming **PDUFA date** for subcutaneous Opdivo in December, aimed at improving patient experience and reducing healthcare costs [4][29] - Strong growth in key products: - **Camzyos**: Cardiovascular drug for obstructive HCM, doubled sales compared to last year [5] - **Breyanzi**: Cell therapy for large B-cell lymphoma, also doubled sales [5] - **Reblozyl**: First-line MDS treatment, doubled sales [5] Future Growth and Clinical Trials - Multiple Phase III data readouts expected between now and 2026, including indications for schizophrenia and Alzheimer's disease [6][12] - **Milvexian**: Expansion of patient population with important Phase III studies planned for ACS and secondary stroke prevention [7][12] - Focus on driving efficiencies with a **$1.5 billion savings initiative** aimed at improving ROI and growth profile [9] Business Development Strategy - Significant business development activity with nearly **$30 billion** in acquisitions over recent years [14] - Current focus on integrating recent acquisitions and paying down **$10 billion** in debt by 2026 [15][14] - Future strategy includes smaller bolt-on acquisitions and collaborations once integration is complete [15] Market Position and Competitive Landscape - The company is well-positioned in therapeutic areas with high unmet medical needs, particularly in solid tumor oncology and neuro products [17][18] - Cobenfy is expected to address significant unmet needs in Alzheimer's disease and other indications, with potential for multibillion-dollar revenue [18][19] Regulatory Environment and Industry Resilience - The company remains confident in navigating regulatory changes and emphasizes the resilience of the healthcare industry [33] - Focus on delivering innovative medicines that address serious unmet medical needs while managing costs [33] Conclusion - Bristol-Myers Squibb is poised for growth with a strong pipeline, strategic focus on execution, and a commitment to addressing unmet medical needs in various therapeutic areas. The company is actively managing its business development strategy while preparing for significant product launches and clinical trial outcomes in the coming years [2][12][15].

On October 31, Bristol-Myers Squibb (NYSE: BMY ) released financial results for the third quarter of 2024 , which not only beat Wall Street analysts' expectations by a wide margin but also pleasantly surprised me.With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceu ...

PHILADELPHIA, PENNSYLVANIA - NOVEMBER 07: Allyson McMillan-Youngblood, SVP U.S. Oncology, Bristol ... [+] Myers Squibb & Board Member, Pennsylvania Conference for Women speaks on stage during 2024 Pennsylvania Conference For Women at Pennsylvania Convention Center on November 07, 2024 in Philadelphia, Pennsylvania. (Photo by Marla Aufmuth/Getty Images for Pennsylvania Conference For Women )Getty Images for Pennsylvania Conference For WomenBristol Myers Squibb stock (NYSE: BMY) was up 10% on Monday, November ...

Key Points **Industry/Company Involved**: - Bristol-Myers Squibb Company (NYSE:BMY) **Core Points and Arguments**: - **Pipeline Strength and Portfolio Changes**: Bristol Myers Squibb has strengthened its pipeline with the addition of companies like Mirati, Karuna, and RayzeBio, expanding beyond immune-oncology. The company has also prioritized certain programs and removed others that were not meeting expectations. - **Research and Development (R&D) Productivity**: The company aims to increase the number of Investigational New Drug (IND) applications, reduce the time from IND approval to first indication approval, and increase the positive outcomes from INDs. - **COBENFY**: COBENFY, a treatment for schizophrenia, has shown promising results and is expected to have multiple indications over the next decade. The company is also exploring its potential in bipolar mania, Alzheimer's disease agitation, and other conditions. - **Milvexian**: Milvexian, a Factor 11 inhibitor, is in Phase III clinical trials for atrial fibrillation, acute coronary syndrome, and stroke prevention. The company remains confident in the drug's potential despite recent competitive challenges. - **CAR-T Therapy**: Bristol Myers Squibb is exploring the potential of CAR-T therapy in autoimmune diseases, including lupus and multiple sclerosis. The company has seen promising results in early trials and is actively researching other mechanisms for resetting immune memory. - **Immunology**: The company is developing a range of immunology assets, including Sotyktu, nivolumab, and relatlimab. The company is also exploring combinations of these drugs to improve outcomes for patients with various conditions. - **Multiple Myeloma**: Bristol Myers Squibb is taking a multi-modality approach to multiple myeloma, including small molecules, cell therapies, and combinations of these therapies. - **Hematology**: The company has a robust pipeline in hematology, including Golcadomide, mezigdomide, and BCL6 LDD. - **Cardiovascular Disease**: The company is developing MYK-224, a second cardiac myosin inhibitor, for the treatment of heart failure with preserved ejection fraction (HFpEF). - **Respiratory Diseases**: The company is developing LPA1, a treatment for idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PPF). **Other Important Points**: - **IRA Legislation**: The company expressed concerns about the potential impact of the IRA legislation on small molecule drugs and the potential for changes to the nine-year versus 13-year discussion. - **ASH Meeting**: The company is expected to present data on various assets at the upcoming ASH meeting, including Golcadomide, mezigdomide, GPRC5D, and BCL6 LDD. - **Future Data**: The company highlighted several data sets that it is excited about in the next 12 to 18 months, including milvexian, GPRC5D, COBENFY, SLE for Sjogren's, anti-TAL, FAAH and MAGLipase inhibitor, radioligand therapy in breast cancer and small cell lung cancer, GPC3 for radioligand therapy, and CCR8 in oncology.

Bristol Myers Squibb Company (BMY) touched a 52-week high of $56.8 on Nov. 6.  The stock is currently trading at $54.14. This biotech giant has been having a good run for the past three months, regaining its lost territories and giving anxious investors a ray of hope.Shares of BMY have risen 20.1% in the past six months compared with the industry’s growth of 5.3%. The stock has also outperformed the sector and the S&P 500 during this period.On Oct. 31, Bristol-Myers reported better-than-expected third-quart ...

The biopharmaceutical sector showed signs of recovery in the third quarter of 2024, fueled by increased investor optimism following the U.S. Federal Reserve’s interest rate cuts in September. According to GlobalData, the top 20 global biopharmaceutical companies saw a 2% rise in their combined market capitalization, reaching $4.3 trillion by the end of September, up from $4.2 trillion in June. This rebound highlights the industry’s potential for growth despite challenges earlier in the year.Bristol-Myers Sq ...